GSK3A and Other metabolic disease: Key therapeutic targets identified through in silico analysis include inflammatory mediators (ALOX15, ALOX5, PTGES, and NOS2) and metabolic regulators (GSK3A and PI4KB), providing mechanistic insights into both traditional uses and potential novel applications, particularly for chronic inflammatory and metabolic disorders.